SAN DIEGO, Feb. 12, 2014 /PRNewswire/ -- Mesa Biotech, Inc., a privately-held, molecular diagnostic company that has developed an affordable, easy-to-use, disposable molecular test for Influenza A/B, today announced that William Brody, M.D., Ph.D. has joined the company as Chairman of the Board. Dr. Brody brings to Mesa Biotech more than 30 years of experience in medical devices, healthcare, and academia. "Bill is a highly accomplished and respected leader in the medical device and healthcare fields, and we are thrilled to have him join our Board," said John Bradley, Chief Executive Officer of Mesa Biotech. "His extensive experience in leading and advising companies, combined with his deep understanding of the healthcare landscape, will be invaluable as we continue to grow our business and bring our innovative molecular diagnostic test to market." Dr. Brody currently serves as the President of the Salk Institute for Biological Studies. Prior to joining the Salk Institute, he served as President of The Johns Hopkins University from 1996 to 2009. Before joining Johns Hopkins, Dr. Brody was Provost of the Academic Health Center and Director of the Department of Biomedical Engineering at the University of Minnesota. He also held faculty appointments in both radiology and electrical engineering. Dr. Brody is a member of the National Academy of Engineering and the Institute of Medicine. He is also a Fellow of the American Academy of Arts and Sciences, the American Institute of Medical and Biological Engineering, and the IEEE. He serves on the Board of Directors of several public and private companies, including Medtronic, Inc., and Integra LifeSciences Holdings Corporation. Dr. Brody received his B.S. and M.S. degrees in Electrical Engineering from the Massachusetts Institute of Technology and his M.D. and Ph.D. degrees from Stanford University. "I am very excited to join Mesa Biotech as Chairman of the Board," said Dr. Brody. "The company has developed a truly innovative molecular diagnostic test that has the potential to transform the way influenza is diagnosed and treated. I look forward to working with the team to bring this important product to market." About Mesa Biotech, Inc. Mesa Biotech, Inc. is developing an affordable, easy-to-use, disposable molecular test for Influenza A/B. The company's technology platform is based on polymerase chain reaction (PCR) amplification, which is the gold standard for molecular diagnostics. The company's test is designed to be used in point-of-care settings, such as physician offices, clinics, and emergency rooms. Mesa Biotech is headquartered in San Diego, California. Contact: John Bradley Chief Executive Officer Mesa Biotech, Inc. jbradley@mesabiotech.com